bpc-157 human dosing protocol BPC-157 Dosing (Common Protocols) πΉ Oral / Subcutaneous β’ 500 mcg daily β’ Duration: 6 weeks πΉ Intramuscular / Peritendinous β’ 1 mg daily β’ Duration: 6 weeks β οΈ Note: Not approved BPC-157 (10mg Vial) Dosage Protocol
Description
Weeks 612: Cleaner body composition across the whole cycle

Current Neuropharmacology 2016

BPC-157s collagen remodelling properties (MMP upregulation, type I collagen synthesis modulation) and cytoprotective effects on oxidatively stressed cells are mechanistically relevant to TM biology
For the Andean communities, the Apu Ausangate is not just a mountain: it is a living being, a spiritual protector
